Motesanib Gets Green Light In Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen/Takeda now altering Phase III design for a smaller patient pool.
You may also be interested in...
Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.
Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.
After Combining Assets, Takeda/Millennium Outline Oncology Strategy
With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.